financetom
Business
financetom
/
Business
/
AI startup Perplexity adds shopping features as search competition tightens
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
AI startup Perplexity adds shopping features as search competition tightens
Nov 19, 2024 9:22 PM

(Reuters) - Artificial intelligence search startup Perplexity on Monday launched a shopping hub to attract users, in a bid to beef up its platform as it attempts to take on Alphabet-owned Google's dominance in the search engine space.

The firm, backed by Amazon founder Jeff Bezos and leading AI chipmaker Nvidia ( NVDA ), will give users product cards showing relevant items in response to questions related to shopping.

Each card provides product details in a visual format, the company said.

The new feature is powered by platform integrations including Shopify ( SHOP ), which gives access to recent and relevant information on products from businesses on the Canadian e-commerce platform globally that ship to the United States.

E-commerce platforms have focused on employing more AI-powered tools in an effort to pull in more merchants.

Perplexity's online shopping-focused rollout includes 'Snap to Shop' - a visual search tool that shows products based on users' photos of an item.

The features are first launching in the United States and will later expand to other markets, the timeline for which was not specified.

Perplexity is also introducing a 'Merchant Program' to allow retailers to share product information with the company.

The startup is raising new investment that would value it at $9 billion, Reuters had reported earlier in November.

Perplexity has been looking to expand its offerings, with OpenAI now a direct competitor after the generative AI pioneer added a set of new search functions to ChatGPT.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Apollo Silver Seeking $10 Million in a Private Placement of Shares; Plans Share Consolidation
Apollo Silver Seeking $10 Million in a Private Placement of Shares; Plans Share Consolidation
Oct 3, 2024
12:12 PM EDT, 10/03/2024 (MT Newswires) -- Apollo Silver ( APGOF ) said Thursday it is seeking to raise $10 million in a private placement of shares and plans to consolidate its shares following the offering. The company said it is looking to place up to 50-million shares priced at $0.20 each in the financing. Proceeds will be used to...
Huntington Ingalls Wins Research Project With Defense Department
Huntington Ingalls Wins Research Project With Defense Department
Oct 3, 2024
12:19 PM EDT, 10/03/2024 (MT Newswires) -- Huntington Ingalls Industries ( HII ) said Thursday that its Mission Technologies division won a task order to enhance navigation and autonomy technologies for the US Department of Defense and specifically for the US Air Force. A Huntington Ingalls team at Wright-Patterson Air Force Base in Dayton, Ohio, will conduct research for the...
Market Chatter: Microsoft's Edge Browser Has Unfair Advantages, Rivals Allege
Market Chatter: Microsoft's Edge Browser Has Unfair Advantages, Rivals Allege
Oct 3, 2024
12:15 PM EDT, 10/03/2024 (MT Newswires) -- Microsoft ( MSFT ) provides an unfair advantage to its Edge web browser, and the company should face strict European Union regulators rules, three rival browsers and a group of web developers said in a letter to the European Commission, Reuters reported Thursday. Vivaldi, Waterfox, Wavebox and Open Web Advocacy said they support...
Bristol-Myers Squibb's Opdivo Gets FDA Approval As Treatment for Resectable Non-Small Cell Lung Cancer
Bristol-Myers Squibb's Opdivo Gets FDA Approval As Treatment for Resectable Non-Small Cell Lung Cancer
Oct 3, 2024
12:16 PM EDT, 10/03/2024 (MT Newswires) -- Bristol-Myers Squibb's ( BMY ) nivolumab (Opdivo) in combination with platinum-doublet chemotherapy was approved by the Food and Drug Administration as a neoadjuvant treatment for resectable non-small cell lung cancer in adults, the regulator said Thursday. The decision was based on a randomized, double-blind, placebo-controlled study involving 461 patients with previously untreated and...
Copyright 2023-2026 - www.financetom.com All Rights Reserved